Johnson & Johnson (JNJ), the world’s biggest maker of health-care products, is exploring a sale of its Cordis unit, which pioneered the market for drug-coated heart stents, a person with knowledge of the matter said.
The division, which sells products including catheters and stents, may fetch as much as $2 billion, said the person, who asked not to be identified because the information is private. The process is in the early stages, the person said.
The medical-devices business, which includes Cordis, is J&J’s second-biggest behind pharmaceuticals and showed the weakest growth in the second quarter. Revenue at the unit rose less than 1 percent to $7.24 billion, according to a statement July 15, as total sales climbed 9 percent to $19.5 billion. About three years ago, after losing ground to rivals, Cordis said it would abandon the market for drug-coated heart stents and focus on other products.
A spokeswoman for J&J, based in New Brunswick, New Jersey, declined to comment.
Last month, J&J Chairman and Chief Executive Officer Alex Gorsky said the company was open to divesting smaller business.
Earlier this year, J&J agreed to sell its Ortho-Clinical Diagnostics business, which sells more than 120 tests for everything from high cholesterol to hormones, to Carlyle Group LP for about $4 billion.
To contact the editors responsible for this story: Mohammed Hadi at firstname.lastname@example.org Elizabeth Wollman, Andrew Pollack